Drug Index


Mechanism :

The mechanisms of action of vincristine remain under investigation. The mechanism of action of vincristine has been related to the inhibition of microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage.

Indication :

  • Acute lymphoblastic leukemia
  • Hodgkin’s disease
  • Non-Hodgkin’s lymphoma
  • Sarcomas
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Wilms tumour

Contraindications :

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome should not be given vincristine. Not for intrathecal use. When chemotherapy is being given in conjunction with radiation therapy through portals which include the liver, the use of vincristine should be delayed until radiation therapy has been completed.

Dosing :

Acute leukemia:
1.5-2 mg/m², every week, IV. Start with 0.05/kg/dose <10 kg every week, intravenous in children <10 kg.

Adverse Effect :

Commonly seen adverse reactions are alopecia, abdominal pain, pain in jaw, bones and joints, peripheral neuropathy, constipation, autonomic neuropathy.

Others: Neuropathic pain, sensory loss, paresthesia, difficulty in walking, loss of deep tendon reflexes, muscle wasting, ataxia, paresis, foot drop and cranial nerve palsies, especially ocular palsies and laryngeal nerve paralysis, pharyngeal pain, parotid gland pain, bone pain, back pain, limb pain and myalgias. Convulsions, frequently with hypertension, have been reported in a few patients receiving vincristine. Leukopenia, anemia and thrombocytopenia, constipation, abdominal cramps, paralytic ileus, diarrhea, weight loss, nausea, vomiting, oral ulceration, intestinal necrosis and/or perforation, and anorexia have occurred.

Interaction :

Phenytoin: Vincristine may reduce serum levels of phenytoin.
Nifedipine, Itraconazole, Cimetidine or Ranitidine: Vincristine plasma clearance can be reduced.
L-asparaginase: May reduce hepatic clearance of vincristine.
Vinca alkaloid: Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids.
Mitomycin: Serious when there is pre-existing pulmonary dysfunction.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in normal renal function
HDUnlikely to be dialysed. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDUnlikely to be dialysed. Dose as in normal renal function

Hepatic Dose :

If the serum bilirubin is between 1.5 to 3 mg/dL or the transaminase levels are 2 to 3 times the upper limit of normal (ULN): Give half the dose.
Do not use if serum bilirubin is greater than 3 times the upper limit of normal.
02/16/2024 17:12:29 Vincristine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0